27
Aug
2018
Tag: customer advocacy
19
Feb
2018
Bionest
Reinventing Medical Affairs to the Benefit of All
The concept of patient-centric drug development has been a frequent topic of discussion in recent years. Increasingly, companies have moved to adopt practices that create more active, networked relationships and interactions between physicians, patients, advocates and drug developers. The aim of such practices is to better respond to patient and physician needs and concerns, while...
6
Apr
2016
Bionest
“Beyond the Pill” — Part Two: Value-Added Services Offer Benefit to Multiple Audiences
In our first “Beyond the Pill” post, we discussed the increasing move towards patient-centric programs that go past an actual prescription to help build relationships with patients and physicians and facilitate the provision of a number of related services to improve compliance and treatment outcomes and keep patients on drug long-term. The benefit of such...
31
Mar
2016
Bionest
“Beyond the Pill,” Part One: Value-Added Services Increasingly Needed Due to Changing Nature of Therapies
The notion of patient-centricity has gained increasing attention from drug developers and others in recent years, mostly in the area of chronic diseases and those requiring complex therapies. But value-added services, which go beyond simple initiatives addressed to patient compliance and access to therapy, are also gaining increasing attention from a variety of other audiences,...
8
Mar
2016
Bionest
Personalized Cancer Therapies: Time to Take Lessons from “Orphan Drugs”
We recently wrote about rare disease drug development and commercialization, and why such franchises succeed better within small companies or perhaps as stand-alone, independently operating units of larger firms. When the patient population targeted by a particular therapy is small, success depends on a highly patient-centric approach to both drug development and commercialization. One must...
1
Mar
2016
Bionest
Trends to Watch in 2016 – Part 2
We started the year off in January by reviewing three of the major trends of 2015 and reflecting on where we saw events headed in 2016. In part 2 of this post, which follows yesterday’s celebration of Rare Disease Day, we’d like to discuss two further areas where we expect to see increasing focus...
24
Feb
2016
Bionest
Orphan Drug Franchises Best Left to Mature Alone
Commercial success in the rare disease field depends on a highly patient-centric approach that connects effectively with rare disease patient communities at a senior management level and focuses on access and interactions with thought leaders and physicians, rather than on selling drug features and benefits. This is the topic of our latest contributed article for...
15
Dec
2015